Cronos Group Inc.

NASDAQ:CRON

Drug Manufacturers - Specialty & Generic

Healthcare
$3.17 -0.56%

-$0.02 today

Market cap
$1.16B
Beta
1.25
P/E (TTM)
-488.3
EPS (TTM)
-$0.01
52W Low $1.84High $3.43

Volume 1.13M

Average 1.51M

CRON Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Cronos Group Inc.NASDAQ: CRON

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit grows, but more slowly than its trailing trend

Q1 FY2026 gross profit of $18.47M rose 34.5% year over year, behind the +95.9% change in trailing-twelve-month gross profit. Sequentially, it rose 14.1% from the prior quarter. Over 3 fiscal years it compounded at +58.7% a year.

Context

  • Gross profit amounted to 41.4% of revenue in FY2025, up 19.9 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +34.5% toward the trailing-twelve-month pace of +95.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$18.47M+14.1% QoQ
Last fiscal yearDec 2025
$61.7M+144.9% YoY
LTMMar 2026
$67.49M+95.9% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+34.5%——
1 year+144.9%——
3-year CAGR+58.7%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
61.7M USD
Year-over-year change
+144.9%

Gross Profit vs competitors

How CRON compares with its peers on the latest reported figures

  • CRON's LTM Mar 2026 gross profit of $67.49M is the 7th highest of the 11 companies compared; the peer median is $257.57M.
  • Its year-over-year change of +95.9% is the 4th highest of 11, against a peer median of +10.8%.
  • Gross profit amounts to 32.8% of revenue for CRON, versus a peer median of 76.8%.
CRON Competitors Peer median
Gross Profit for CRON and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EMBCEmbecta Corp.LTM Mar 2026$651.8M -5.2%-4.3%62.5%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$607.18M +545.5%—86.5%
PCRXPacira BioSciences, Inc.LTM Mar 2026$583.01M +6.9%+7.2%79.3%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$483.18M +26.1%+30.3%60.7%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$341.13M -7.6%+12.7%47.3%
PHATPhathom Pharmaceuticals, Inc.LTM Mar 2026$174.02M +146.5%—84.9%
CRONCronos Group Inc.LTM Mar 2026$67.49M +95.9%+58.7%32.8%
IRMDIRadimed CorporationLTM Mar 2026$66.3M +14.7%+15.9%76.8%
XNCRXencor, Inc.LTM Jun 2026$45.46M -54.8%—43.3%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$19M +2140.8%—95.0%
BBOTBridgeBio Oncology Therapeutics Inc.LTM Mar 2026-$186K -19.2%——
Peer median (excluding CRON) $257.57M+10.8%+12.7%76.8%

Competitors are the stored peer set for CRON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue64.56M86.75M87.24M117.62M149.15M
Cost of Revenue82.15M71.31M75.33M92.42M87.45M
Gross Profit(17.59M)15.44M11.91M25.2M61.7M
Gross Margin-27.3%17.8%13.7%21.4%41.4%
Research & Development21.84M13.13M5.84M4.23M4.45M
Selling, General & Admin121.68M100.73M80.93M76.82M63.76M
Operating Expenses274.38M126.86M96.71M101.73M79.54M
Depreciation & Amortization15.4M13.12M8.11M9.34M14.48M
EBITDA(150.13M)(91.27M)(71.8M)(50.21M)(3.36M)
EBITDA Margin-232.5%-105.2%-82.3%-42.7%-2.3%
Operating Income(291.97M)(111.43M)(84.8M)(76.53M)(17.84M)
Operating Margin-452.2%-128.4%-97.2%-65.1%-12.0%
Interest Income9.07M22.51M51.24M52.02M40.66M
Interest Expense27K13K000
Other Income / Expenses163.46M(9.58M)11.13M113.12M419.21K
Income Before Tax(128.51M)(121M)(73.67M)36.59M(17.42M)
Pre-Tax Margin-199.1%-139.5%-84.4%31.1%-11.7%
Income Tax Expense(431K)34.18M(3.23M)(3.44M)(14.44M)
Net Income(396.11M)(168.73M)(73.96M)41.08M(9.61M)
Net Margin-613.5%-194.5%-84.8%34.9%-6.4%
EPS (Basic)(1.07)(0.45)(0.19)0.11(0.03)
EPS (Diluted)(1.07)(0.45)(0.19)0.11(0.03)
Weighted Avg Shares370.39M376.96M403.4M382.06M385.31M
Weighted Avg Shares (Diluted)370.39M376.96M380.97M385.56M385.31M

Cronos Group Inc.

NASDAQ:CRON

Intrinsic Alpha fair value

Locked

Current Price

$3.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.